Management of advanced genitourinary malignancies has undergone a major transformation in recent years, due to the advent of novel targeted and immunotherapeutic options. The current treatment scenario continue to expand providing new standards of care that require an increasingly complex and challenging management of patients.  Assessment of treatment-related risk and benefits is required and a better knowledge of clinical and molecular features of these diseases is strongly warranted. Results from ongoing studies and validation of predictive/prognostic biomarkers are expected to provide more treatment options and improve outcomes of patients affected by genitourinary malignangies. During this meeting the most recent advances in medical treatment of genitourinary malignancies will be discussed to guide optimal integration of evidence into practice.

Scheda di registrazione